Elevated mutant frequencies in lymphoid tissues persist throughout plasmacytoma development in BALB/c.lambdaLIZ mice. Cancer Res 1999 Aug 01;59(15):3621-6
Date
08/14/1999Pubmed ID
10446972Scopus ID
2-s2.0-0033179682 (requires institutional sign-in at Scopus site) 10 CitationsAbstract
Using the phage lambdaLIZ-based transgenic in vivo mutagenesis assay, the mean mutant frequencies in the target gene, lacI, were found to be significantly increased in lymphoid tissues of congenic BALB/c.lambdaLIZ N5 mice in the terminal stage of a plasmacytoma induction experiment, 213-280 days after the first i.p. injection of the plasmacytomagenic agent pristane (2,6,10,14-tetramethylpentadecane). In plasmacytoma-bearing mice (n = 7), mutant frequencies in the spleens and mesenteric lymph nodes were elevated 2.46-fold and 5.35-fold, respectively, when compared with age-matched controls. In plasmacytoma-negative mice (n = 11), mutant frequencies were increased 2.30-fold (spleens) and 3.48-fold (mesenteric nodes). These results, interpreted in conjunction with our previous findings (K. Felix et al., Cancer Res., 58: 1616-1619, 1998) of approximately 3-fold elevations in pristane-induced splenic mutagenesis on day 42 postpristane, indicate that increased mutant levels in lymphoid tissues persist throughout plasmacytomagenesis in genetically susceptible BALB/c mice.
Author List
Felix K, Kelliher KA, Bornkamm GW, Janz SAuthor
Siegfried Janz MD Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AnimalsBacterial Proteins
Carcinogens
DNA
DNA Mutational Analysis
DNA, Neoplasm
Disease Progression
Escherichia coli Proteins
Female
Genes, Reporter
Lac Operon
Lac Repressors
Lymph Nodes
Lymphoid Tissue
Male
Mice
Mice, Inbred BALB C
Mice, Inbred C57BL
Mice, Transgenic
Mutagenesis
Peritoneal Neoplasms
Plasmacytoma
Repressor Proteins
Spleen
Terpenes
